Abstract Details

Title Socioeconomic Status and Its Impact on Clinical and Radiographic Findings in MOGAD at Diagnosis

Topic Autoimmune Neurology

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 8-010

Objective To investigate statistically significant associations between socioeconomic status, demographics, radiographic findings, and clinical symptoms in MOGAD patients.

Background Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is a central nervous system demyelinating disorder with a wide range of clinical and radiographic features. While prior studies have explored clinical and radiological findings in MOGAD, the influence of socioeconomic status (SES) on these variables has not been well studied.

Design/Methods

A retrospective analysis was conducted on 45 adult MOGAD patients from the greater Houston area using electronic health records. Patients were grouped by socioeconomic status (SES) based on income percentiles (below the 20th) and the Area of Deprivation Index (ADI). Proportions were compared to assess for statistically significant associations between SES, demographics, radiographic findings, and clinical symptoms.

Results Patients with ADI scores greater than 5 were linked to lower proportions of white patients (18.8% vs 65.5%, n=16 vs n=29, p=0.003), higher proportions of black patients (37.5% vs 6.9%, n=16 vs n=29, p=0.010), incomes below the 20th percentile (53.3% vs 6.9%, n=15 vs n=29, p=<0.001), thoracic spine lesions (66.7% vs 30.0%, n=12 vs n=20, p=0.043), intracanalicular optic nerve lesions (88.9% vs 37.5%, n=9 vs n=16, p=0.013), and weakness (56.3% vs 20.7%, n=16 vs n=29, p=0.015).

Conclusions Socioeconomic status, as measured by income and ADI, appears to significantly influence both clinical presentation and radiographic findings in MOGAD patients at diagnosis. Lower SES was associated with higher rates of low income earners, black patients, thoracic spine lesions, and weakness. These findings underscore the need to consider SES in both clinical evaluation and management decisions for patients with MOGAD.

Authors/Disclosures
Amna M. Ali, BA PRESENTER	Ms. Ali has nothing to disclose.
James Edwards, Medical Student	Mr. Edwards has nothing to disclose.
Bohan Kim, BA	Mr. Kim has nothing to disclose.
Jennifer Cheng, BS	Ms. Cheng has nothing to disclose.
Ivy Zheng, BSA	Miss Zheng has nothing to disclose.
Ashish Balar, MBBS	Dr. Balar has nothing to disclose.
Rajesh K. Gupta, MBBS (UTHealth)	Dr. Gupta has nothing to disclose.

��ɫ��

��ɫ��